allogeneic rituximab conjugated gamma delta t-cells ace1831
allogeneic rituximab conjugated gamma delta t-cells ace1831: 2 clinical trials tracked.
allogeneic rituximab conjugated gamma delta t-cells ace1831 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
What is verified about allogeneic rituximab conjugated gamma delta t-cells ace1831, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (2)
Phase 1b/2a Prospective, Open Label, Multicenter, Two-Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Immunoglobulin G4-Related Disease
Primary endpoint: Safety and Tolerability of ACE1831 as Assessed by Adverse Events, Clinical Laboratory Tests, Physical Examinations, ECGs, and Vital Signs
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies
Primary endpoint: Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs)